	Application No.	Applicant(s)
Notice of Allowability	09/803,628	CURATOLO ET AL.
	Examiner	Art Unit
	Konata M. George	1616
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to <u>RCE filed July 19, 2005</u> .		
2. X The allowed claim(s) is/are 149,150,152,164,165,168,169,171-176,178,179,182,185,187,189,208,210,212 and 215-220.		
3. The drawings filed on are accepted by the Examiner.		
 4. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some* c) None of the: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)). * Certified copies not received: 		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
5. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
6. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1) 🔲 hereto or 2) 🔲 to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1, each sheet. Replacement sheet(s) should be labeled as such in the		
7. DEPOSIT OF and/or INFORMATION about the deposit attached Examiner's comment regarding REQUIREMENT I		
Attachment(s)	_	
1. Notice of References Cited (PTO-892)	5. Notice of Informal Page 1	atent Application (PTO-152)
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	 Interview Summary Paper No./Mail Dat 	
3. Information Disclosure Statements (PTO-1449 or PTO/SB/0 Paper No./Mail Date 7/19 2005	8), 7. Examiner's Amendm	nent/Comment
4. Examiner's Comment Regarding Requirement for Deposit	8. 🛛 Examiner's Stateme	nt of Reasons for Allowance
of Biological Material	9. Other	

DETAILED ACTION

Claims 149, 150, 152, 164, 165, 168, 169, 171-176, 178, 179, 182, 185, 187, 189, 208, 210, 212 and 215-220 are pending in this application.

Request for Continued Examination (RCE)

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after allowance or after an Office action under *Ex Parte Quayle*, 25 USPQ 74, 453 O.G. 213 (Comm'r Pat. 1935). Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, prosecution in this application has been reopened pursuant to 37 CFR 1.114. Applicant's submission filed on July 19, 2005 has been entered.

Information Disclosure Statement

2. The information disclosure statement (IDS) submitted on July 19, 2005 was noted and the submission is in compliance with the provisions of 37 CFR 1.97.

Accordingly, the examiner has considered the information disclosure statement.

Action Summary

3. The rejection of claims 149, 150, 152, 164, 165, 168, 169, 171-176, 178, 179, 182, 185, 187, 189, 208, 210, 212 and 215-220 are rejected under 35 U.S.C. 103(a) as

being unpatentable over Curatolo et al. (USP 5,605,889) in view of Urquhart et al. (USP 4,851,231) is hereby withdrawn with respect to applicants arguments.

Statement of Reasons for Allowance

4. The following is an examiner's statement of reasons for allowance:

The claims are allowable over the cited prior art because the prior art does not teach, disclose nor make obvious a controlled release dosage form of azithromycin. The closet prior art, most notably Curatolo et al. (5,605,889) and Urquhart et al. (4,434,153), is drawn to rapid release dosage forms (Curatolo), or does not teach controlled release dosage forms (Urquhart).

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Conclusion

5. Claims 149, 150, 152, 164, 165, 168, 169, 171-176, 178, 179, 182, 185, 187, 189, 208, 210, 212 and 215-220 are allowed.

Telephone Inquiries

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Konata M. George, whose telephone number is

Art Unit: 1616

(571) 272-0613. The examiner can normally be reached from 8AM to 6:30PM Monday to Thursday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Kunz, can be reached at (571) 272-0887. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 872-9306 for regular communications and for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (571) 272-1600.

Konata M. George

SHELLEY A. DODSON PRIMARY EXAMINER